In vitro activity of Bay 12-8039, a new 8-methoxyquinolone

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antimicrobial resistance is a growing global health concern.
• Novel antimicrobial agents are needed to combat resistant bacterial infections.
• Fluoroquinolones are a critical class of antibiotics used to treat various infections.

Purpose of the Study:

• To evaluate the in vitro activity of a novel fluoroquinolone, Bay 12-8039.
• To compare the antimicrobial spectrum of Bay 12-8039 with ciprofloxacin and ofloxacin.
• To assess the activity of these agents against a diverse range of recent clinical bacterial isolates.

Main Methods:

• Determination of Minimum Inhibitory Concentrations (MICs) for Bay 12-8039, ciprofloxacin, and ofloxacin.
• Testing against 820 recent clinical isolates, including Gram-negative and Gram-positive bacteria, and anaerobes.
• Statistical analysis, including regression analysis, to compare antimicrobial activity and assess correlations.

Main Results:

• Ciprofloxacin demonstrated greater activity against Enterobacteriaceae and Pseudomonas aeruginosa compared to Bay 12-8039 and ofloxacin.
• Bay 12-8039 exhibited superior activity against non-fermenting Gram-negative bacteria (excluding P. aeruginosa), staphylococci, streptococci, enterococci, and anaerobic bacteria.
• Regression analysis revealed a strong correlation among the MICs of the tested quinolones.

Conclusions:

• Bay 12-8039 possesses a distinct antimicrobial spectrum compared to ciprofloxacin and ofloxacin.
• The novel fluoroquinolone shows promising activity against a range of challenging pathogens, including Gram-positive bacteria and anaerobes.
• Further investigation into Bay 12-8039 is warranted for its potential clinical applications in treating infections caused by susceptible organisms.